New Delhi, Aug 16 (IANS) India’s drugs and pharmaceuticals exports are continuing to maintain their steady growth with an 8.36 per cent increase to $2.31 billion during July this year as the country’s cost-effective generic medicines continue to gain popularity in advanced western nations.
The country’s drugs and pharmaceuticals exports increased 9.67 per cent year-on-year to $27.9 billion in 2023-24 and the growth is continuing in the current financial year as well.
The US accounts for over 31 per cent of India’s total pharma exports, followed by the UK and Netherlands (about 3 per cent each).
Apart from Brazil and South Africa, Ireland and Sweden are new additions to the Indian export market.
India’s pharmaceutical sector’s export share increased to 6.4 per cent in the fiscal year 2023-2024 (FY24) from 5.8 per cent in 2018-2019 (FY19), and an uptick in export value to $27.9 billion from $19.1 billion, according to the latest Economic Survey.
“India’s pharmaceutical sector has strengthened its position on the global stage. The market, currently valued at $50 billion, is the third-largest worldwide by volume. Known as the ‘pharmacy of the world’, India offers approximately 60,000 generic brands across 60 therapeutic categories, contributing 20 per cent to global generic drug exports. Eight of the top 20 global generic companies are based in India,” according to the Economic Survey.
The pharmaceutical industry in India is expected to reach $65 billion by 2024 and to $130 billion by 2030.
The survey pointed out that the sector maintains high compliance standards with 703 United States Food and Drug Administration (US FDA)-approved facilities, 386 European Good Manufacturing Practice (GMP)-compliant plants, and 241 World Health Organisation Good Manufacturing Practice (WHO-GMP)-approved plants.
In December 2023, revised manufacturing rules under Schedule-M were introduced to align with global standards and enhance quality control.
The survey also found that the PLI scheme for medical devices has a beneficial impact, narrowing the gap between imports and exports.
Domestic production now includes computed tomography (CT) scan machines, magnetic resonance imaging (MRI) machines and other medical devices.
The PLI scheme for bulk drugs has approved 48 projects with a committed investment of Rs 3,938.6 crore to bolster local manufacturing.
Financial assistance through Pharmexcil, an Export Promotion Council, is also provided under Market Development Assistance and Market Access Initiative Schemes to exporters of pharmaceutical products particularly small and medium size exporters to promote their exports in various countries.
–IANS
sps/rad
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
